Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133532) titled 'An Exploratory Study on the Prevention of Insulin Resistance in Patients with Schizophrenia Spectrum Disorders Treated with Olanzapine by N-Acetylcysteine' on Sept. 29.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Beijing An Ding Hospital, Capital Medical University
Condition:
Schizophrenia spectrum disorder
Intervention:
NAC Group:treating with NAC
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-06
Target Sample Size: NAC Group:43;Control group:43;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.htm...